国药股份
(600511)
| 流通市值：159.81亿 | | | 总市值：217.90亿 |
| 流通股本：5.53亿 | | | 总股本：7.55亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 13,555,320,492.97 | 52,468,280,576.72 | 39,381,301,380.27 | 25,633,950,652.46 |
| 营业收入 | 13,555,320,492.97 | 52,468,280,576.72 | 39,381,301,380.27 | 25,633,950,652.46 |
| 二、营业总成本 | 13,016,129,612.77 | 50,383,129,082.29 | 37,808,187,653.76 | 24,641,402,034.11 |
| 营业成本 | 12,728,593,559.96 | 49,008,442,996.72 | 36,882,467,060.97 | 24,060,477,733 |
| 税金及附加 | 32,949,483.89 | 137,278,338.03 | 103,950,143.4 | 57,928,864.03 |
| 销售费用 | 144,647,024.71 | 724,522,148.23 | 491,126,559.53 | 306,056,493.15 |
| 管理费用 | 100,051,045.73 | 465,457,096.7 | 303,628,278.73 | 201,381,582.3 |
| 研发费用 | 12,764,925.56 | 69,305,717.06 | 43,593,756.03 | 28,015,746.87 |
| 财务费用 | -2,876,427.08 | -21,877,214.45 | -16,578,144.9 | -12,458,385.24 |
| 其中:利息费用 | 6,111,010 | 27,165,852.32 | 20,164,157.8 | 14,966,586.59 |
| 其中:利息收入 | 8,748,193.71 | 56,090,455.02 | 44,555,075.23 | 34,616,570.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 66,164.34 | - | - |
| 加:投资收益 | 128,899,404.06 | 566,776,551.25 | 440,990,983.15 | 293,601,361.38 |
| 资产处置收益 | -36,112.82 | 212,185.96 | 436,715.7 | 548.56 |
| 资产减值损失(新) | -3,854,838.17 | -5,563,843.29 | -9,922,046.21 | -8,207,322.15 |
| 信用减值损失(新) | -59,194,193.83 | -34,099,335.64 | -65,104,303.82 | -53,274,589 |
| 其他收益 | 1,585,472.83 | 9,120,795.19 | 6,020,672.59 | 4,450,139.07 |
| 四、营业利润 | 606,590,612.27 | 2,621,664,012.24 | 1,945,535,747.92 | 1,229,118,756.21 |
| 加:营业外收入 | 259,740.53 | 7,022,668.3 | 6,373,388.24 | 5,575,244.36 |
| 减:营业外支出 | 69,278.41 | 28,544,107.2 | 18,166,671.03 | 8,114,068.54 |
| 五、利润总额 | 606,781,074.39 | 2,600,142,573.34 | 1,933,742,465.13 | 1,226,579,932.03 |
| 减:所得税费用 | 115,266,409.63 | 510,738,987.34 | 377,847,999.35 | 235,096,525.17 |
| 六、净利润 | 491,514,664.76 | 2,089,403,586 | 1,555,894,465.78 | 991,483,406.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 491,514,664.76 | 2,089,403,586 | 1,555,894,465.78 | 991,483,406.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 474,263,852.3 | 1,996,593,114.46 | 1,492,265,301.07 | 948,547,379.33 |
| 少数股东损益 | 17,250,812.46 | 92,810,471.54 | 63,629,164.71 | 42,936,027.53 |
| 扣除非经常损益后的净利润 | 465,082,063.18 | 1,970,533,716.86 | 1,470,144,060.96 | 931,500,919.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.63 | 2.65 | 1.98 | 1.26 |
| (二)稀释每股收益 | 0.63 | 2.65 | 1.98 | 1.26 |
| 八、其他综合收益 | 27,155,628.34 | 23,638,059.9 | 25,861,163.15 | 337,686.56 |
| 归属于母公司股东的其他综合收益 | 27,155,628.34 | 23,638,059.9 | 25,861,163.15 | 337,686.56 |
| 九、综合收益总额 | 518,670,293.1 | 2,113,041,645.9 | 1,581,755,628.93 | 991,821,093.42 |
| 归属于母公司股东的综合收益总额 | 501,419,480.64 | 2,020,231,174.36 | 1,518,126,464.22 | 948,885,065.89 |
| 归属于少数股东的综合收益总额 | 17,250,812.46 | 92,810,471.54 | 63,629,164.71 | 42,936,027.53 |
| 公告日期 | 2026-04-23 | 2026-03-20 | 2025-10-22 | 2025-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |